Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

@inproceedings{Irwin2013SmallME,
  title={Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia},
  author={Mary Elizabeth Irwin and Laura D. Nelson and Janice M. Santiago-O’Farrill and Phillip D. Knouse and Claudia P. Miller and Shana L. Palla and Doris R. Siwak and Gordon B. Mills and Zeev Estrov and Shulin Li and Steven M. Kornblau and Dennis P. M. Hughes and Joya Chandra},
  booktitle={PloS one},
  year={2013}
}
The presence of the Philadelphia chromosome in patients with acute lymphoblastic leukemia (Ph(+)ALL) is a negative prognostic indicator. Tyrosine kinase inhibitors (TKI) that target BCR/ABL, such as imatinib, have improved treatment of Ph(+)ALL and are generally incorporated into induction regimens. This approach has improved clinical responses, but molecular remissions are seen in less than 50% of patients leaving few treatment options in the event of relapse. Thus, identification of… CONTINUE READING
Highly Cited
This paper has 468 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

469 Citations

0100200'14'15'16'17'18'19
Citations per Year
Semantic Scholar estimates that this publication has 469 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…